Key Management

Danny Zanardo, VP Commercial

Danny has over 25 years of commercial experience in Australian and global pharmaceuticals and medical devices. He has held executive positions in both private and ASX listed entities including Admedus Ltd, Roche and Actelion with a track record of successfully commercialising new medical technologies in Europe, North America, Asia Pacific and MENA.

Jacques Schipper, Chief Financial Officer

Jacques brings over 14 years of experience in Finance, Commercial Management & Controller roles. Prior to LTP he has been in senior financial roles at Lion Dairy & Drinks, Anteris Technologies, NL Food, First Quantum Minerals as well having successfully owned and managed several private businesses.

Peter McLennan, Chief Operating Officer

Peter has worked with companies of all sizes worldwide to improve operations and technology and engage with the financial markets. Peter has advised large European enterprises, Australian and New Zealand startups, and Australian government agencies. Peter has also served as a Non-Executive Director on an ASX board for a technology company, bringing valuable insights into governance and strategic direction. Furthermore, Peter worked in London for a US investment bank and as a consultant to Life Science, Agricultural, Industrial, and Technology companies in Australia, giving him extensive financial markets and M&A experience.

Mike Sweeting, VP, US Sales & Marketing

Mike has over 30 years of senior leadership roles in the pharmaceutical industry in commercial sales and market access. Mike currently serves early-stage pharmaceutical and biotech companies as an executive management consultant, most recently, building all functions related to Market Access for Scilex Pharmaceuticals, a San Diego-based startup.

Kip Vought, VP, Regulatory

Kip is a senior pharmaceutical R&D and regulatory executive with over 25 years of experience across major global markets. Successful leadership in preparation of agency meetings (PIND and equivalent, EOP1, EOP2, and PNDA/MAA and regional equivalents) all the way through to the preparation and submission of market applications.

Dr. Monil Shah, VP, Operations & Clinical Development

Monil has over 20 years of pharmaceutical and biotechnology industry experience in drug development. His most recent appointments include Chief Business Officer at Imugene and Chief Development Officer at WindMIL Therapeutics, and Chief Operating Officer of IRX Therapeutics. Previously, Medical Affairs Lead for Immuno-Oncology at Bristol Myers Squibb.

Prof. Geoffrey Strange, VP Medical Affairs

Geoffrey is a senior executive and medical researcher with over 20 years’ experience in the biopharmaceutical and medical industries. He’s been an expert scientific advisor for numerous global pharmaceutical companies including Pfizer, Novartis, Bayer Pharmaceuticals Australia, Glaxo Smith & Kline (GSK) Australia and Edwards LifeSciences.

Lee Rodne, Executive Chairman:

Lee holds over 25 years’ experience in the healthcare and technology sectors and has been in executive leadership roles in both Public and Private enterprises. He previously worked in Fortescue Metals Group and led a healthcare technology spin out (Allied Medical) as its CEO and Managing Director that resulted in increasing its valuation from $800k to a peak of $250m (ASX:AHZ, AVR). He was also the Senior Executive of Sirius Minerals Plc that led to its lead acquisition project and reached a peak market capitalisation of over $1 billion on the London exchange. Lee holds an MBA from the University of St Thomas, Minnesota and B.A. degree in Business Management from St John’s University.